Deals and Data

Deals and Data

Sequenom finds that whole-genome bisulfite sequencing can help distinguish between placental and maternal circulating cell-free DNA. (GenomeWeb, 04/21/15)

Pfizer’s blood cancer drug, inotuzumab, meets 1 of 2 goals in late-stage trial; treated patients were more likely to have complete remission. (Fox Business, 04/21/15)

Merck and TetraLogic Pharmaceuticals enter oncology clinical study for patients with relapsed or refractory solid tumors. (PBR, 04/21/15)

Pfizer’s Xalkori gets Breakthrough Therapy designation for treating patients with rare ROS1-positive form of non-small cell lung cancer. (PharmaTimes Online, 04/21/15)

The Scripps Research Institute and University of Massachusetts identify circuitry in the brain responsible for increased anxiety linked to smoking cessation. (GEN News, 04/22/15)

Astellas Pharma and Potenza Therapeutics to build portfolio of immune-oncology therapeutics. (GEN News, 04/22/15)

VWR to distribute DuPont Diagnostics’ PCR-based pathogen detection technology for the food industry. (GenomeWeb, 04/21/15)

Sanofi offers technical expertise in its partnership with the Canadian National Access Project for Cancer Testing. (GenomeWeb, 04/21/15)

Celgene to develop AstraZeneca’s prized immunotherapy drug for blood cancers. (Reuters, 04/24/15)

FDA approves Eli Lilly’s ramucirumab in combination with FOLFIRI chemotherapy for the treatment of metastatic colorectal cancer. (Healio, 04/24/15)

AbbVie’s NDA for its experimental hepatitis C treatment gets FDA priority review. (Zacks, 04/24/15)

World’s first malaria vaccine (GlaxoSmithKline) could be approved by international regulators for use in Africa by October. (Reuters, 04/24/15)

Merck invests in Ireland plant to manufacture its oncology drug Keytruda, an anti-PD1 mAb. (BioPharma, 04/24/15)

Salk Institute scientists use genome editing technologies to remove mutations in mitochondrial DNA from germline cells; could remove heritable mitochondrial diseases. (GenomeWeb, 04/23/15)

Vical to supply plasmid DNA for HIV vaccine clinical trial in contract with the IPPOX Foundation. (U-T San Diego, 04/22/15)

Celgene to acquire Quanticel Pharmaceuticals for up-to-$485 million as part of the cancer drug discovery collaboration agreement launched 3 ½ years ago. (GEN News, 04/27/15)

Boehringer Ingelheim’s drug to reverse blood thinning granted FDA priority review. (Reuters, 04/23/15)

Ypsomed to manufacture injection system pen components for new Sanofi product line in late 2016. (FDA News, 04/27/15)

Edico Genome to collaborate with Intel to tackle growing concerns surrounding next-generation sequencing data analysis. (GEN News, 04/21/15)

Celgene and Northern Biologics partner to discover and develop first-in-class therapeutic antibodies against cancer and fibrosis. (GEN News, 04/29/15)

Amgen’s skin cancer immunotherapy given marketing approval for its efficacy in melanoma treatment. (Reuters, 04/29/15)

Celgene expands partnership with Agios Pharmaceuticals, partners on another preclinical cancer candidate. (FierceBiotech, 04/29/15)

UC San Diego study suggests global pancreatic cancer rates are highest among countries with the least amount of sunlight. (GEN News, 04/30/15)

Human Longevity receives CLIA certification for its laboratory; focus on building a database of human genotypes and phenotypes. (GenomeWeb, 04/29/15)

Merck enters multi-target discovery and optimization collaboration with PeptiDream for the development of peptides. (PBR, 05/04/15)

ATyr Pharma Inc. to raise $76 million in an IPO; develops medicines for rare diseases. (San Diego Business Journal, 05/03/15)

Pfizer bids for Swedish Orphan Biovitrum AB (SOBI), specializing in medicines for rare and orphan conditions. (Reuters, 04/30/15)

FDA clears GlaxoSmithKline/Theravance's BREO Ellipta inhaler to treat asthma in adults. (PharmaTimes, 04/30/15)

FDA accepts AbbVie and Biogen’s BLA for marketing approval of Zinbryta for relapsing forms of multiple sclerosis. (PBR, 04/30/15)

FDA accepts Otonomy’s NDA for AuriPro for the treatment of middle ear effusion in pediatric patients undergoing tympanostomy tube placement surgery. (PharmaBiz, 04/30/15)

Inovio Pharmaceuticals to raise $76m in public offering, focuses on developing immunotherapies to prevent and treat cancer and infectious diseases. (Philadelphia Business Journal, 04/30/15)

Isis Pharma partners with Bayer HealthCare to bring anticoagulant ISIS-FXIRx to market. (U-T San Diego, 05/04/15)

Salk Institute and Chinese Academy of Science team finds potential molecular driver that accelerates aging, advances knowledge of aging process. (U-T San Diego, 04/30/15)

Novo Nordisk to open $225 million hemophilia treatment manufacturing site in Denmark. (BioSpace, 05/04/15)

Eli Lilly plans to establish Lilly Cambridge Innovation Center to focus on new drug delivery and device approaches. (GEN News, 05/06/15)

Pfizer and 23andMe launch lupus research study to help better understand the genetics of lupus. (PBR, 05/06/15)

GlaxoSmithKline, Fondazione Telethon and Ospedale San Raffaele submit EU application to market investigational gene therapy for the treatment of an ultra-rare white blood cell deficiency condition. (PharmaTimes, 05/05/15)

« Return to Table of Contents